Effect of Diindolylmethane on Estrogen-related Hormones, Metabolites and Tamoxifen Metabolism: Results of a Randomized, Placebo-controlled Trial

Thomson, CA; Chow, Shh; Roe, DJ; Wertheim, Betsy C.; Chalasani, Pavani; Altbach, MI; Thompson, Patrick W; Stopek, A; Maskaranic, G

doi:10.1158/1055-9965.epi-17-0027

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many of the previous studies that evaluated the effects of DIM focused on changes in 2-OHE1, 16-OHE1, and the 2/16 ratio. 6,15,16,24 In addition to the focus on the 2-OHE1 and 16-OHE1, Dalessandri and colleagues also reported urinary E1, E2, and E3 concentrations before and after DIM use, along with urinary 6𝛽-hydroxycortisol (6𝛽-OHC), cortisol, and the 6𝛽-OHC/cortisol ratio, which has shown to be an indication of CYP3A4 enzyme activity. 25 As discussed earlier, regarding DIM, the activity of CYP3A4 in uences production of 16-OHE1 and 4-OHE2, the non-favored estrogen metabolites.…”

Section: Discussionmentioning

confidence: 99%

Exploring the Impact of 3,3’-Diindolylmethane on the Urinary Estrogen Profile of Premenopausal Women

Newman,

Smeaton

2024

Preprint

View full text Add to dashboard Cite

Background 3, 3’-diindolylmethane (DIM) is a phytonutrient derived from cruciferous vegetables that is an often used supplement in the complementary and alternative medicine space. The most common goal for providers when recommending DIM to their patients is to alter estrogen metabolism, yet research into DIM’s effect on the estrogen profile is lacking in the published literature. The objective of this study was to comprehensively evaluate DIM’s effect on the urinary estrogen profile. Methods In this retrospective cohort study, we analyzed data from a clinical laboratory, including urinary estrogen and estrogen metabolite concentrations. Analyte concentrations were determined from dried urine samples using a gas chromatography-tandem mass spectrometry assay. Individuals were separated into 2 groups, either reporting taking DIM (N = 909) or reporting not taking DIM (N = 18,385). Comparisons between individuals in these two groups were made using the Wilcoxon rank sum test. Additionally, we were also able to explore a subset of women who had laboratory results in the database before and after initiating DIM treatment (N = 53). In this subset, differences were assessed with Wilcoxon signed rank tests. Results In the larger group, significant differences were observed in the concentrations of almost every urinary estrogen and estrogen metabolite (with the only exception being 2-methoxyestrone) in the urinary estrogen profiles of those taking DIM compared to those not taking DIM (all P values < 0.001). In the smaller subset of individuals with before and after measurements, differences were only seen in 4 of the urinary estrogens and estrogen metabolites (P < 0.001 for estrone, estradiol, estriol, and 16-hydroxyestrone). Differences in total estrogens were significant in both the larger group and the smaller subset (both with P < 0.001). Additionally, observed differences in the ratios of metabolites followed a similar trend with more significant differences observed in the larger group. Notably, the 2-hydroxyestrone:16-hydroxyestrone ratio increased significantly in both the larger and the before and after group. Conclusions The results of this study provide the most comprehensive evaluation to date of DIM’s effect on the urinary estrogen profile. Additionally, the results demonstrate that the dried urine collection and accompanying assay used captures changes that are similar in direction, but not necessarily magnitude, to previous reports in the literature. Considered together, these two things highlight the clinical validity and utility of this approach to the evaluation of DIM supplementation and suggest the need for additional studies using this approach to fully understand the potential clinical utility of DIM.

show abstract

Section: Discussionmentioning

confidence: 99%

Exploring the Impact of 3,3’-Diindolylmethane on the Urinary Estrogen Profile of Premenopausal Women

Newman,

Smeaton

2024

Preprint

View full text Add to dashboard Cite

show abstract

“…In spite of this, the reduced levels of tamoxifen metabolites raise concerns about the potential interaction between diindolylmethane and tamoxifen, which requires further research. These data will contribute to informing the use of diindolylmethane as a dietary supplement for BC patients receiving tamoxifen, given the widespread and generally unsupported use of dietary supplements by BC survivors [ 175 ].…”

Section: Modulation Of the Microbiota Through Diet As A Potential Adj...mentioning

confidence: 99%

The Interplay between Microbiota and Chemotherapy-Derived Metabolites in Breast Cancer

Plaza‐Díaz

Álvarez‐Mercado

2023

Metabolites

View full text Add to dashboard Cite

The most common cancer in women is breast cancer, which is also the second leading cause of death in this group. It is, however, important to note that some women will develop or will not develop breast cancer regardless of whether certain known risk factors are present. On the other hand, certain compounds are produced by bacteria in the gut, such as short-chain fatty acids, secondary bile acids, and other metabolites that may be linked to breast cancer development and mediate the chemotherapy response. Modeling the microbiota through dietary intervention and identifying metabolites directly associated with breast cancer and its complications may be useful to identify actionable targets and improve the effect of antiangiogenic therapies. Metabolomics is therefore a complementary approach to metagenomics for this purpose. As a result of the combination of both techniques, a better understanding of molecular biology and oncogenesis can be obtained. This article reviews recent literature about the influence of bacterial metabolites and chemotherapy metabolites in breast cancer patients, as well as the influence of diet.

show abstract

Exploring the impact of 3,3’-diindolylmethane on the urinary estrogen profile of premenopausal women

Newman,

Smeaton

2024

BMC Complement Med Ther

View full text Add to dashboard Cite

Background 3,3’-diindolylmethane (DIM) is a phytonutrient derived from cruciferous vegetables that is an often-used supplement in the complementary and alternative medicine space. The most common goal for providers when recommending DIM to their patients is to alter estrogen metabolism, yet research into DIM’s effect on the estrogen profile is lacking in the published literature. The objective of this study was to comprehensively evaluate DIM’s effect on the urinary estrogen profile. Methods In this retrospective cohort study, we analyzed data from a clinical laboratory, including urinary estrogen and estrogen metabolite concentrations. Analyte concentrations were determined from dried urine samples using a gas chromatography-tandem mass spectrometry assay. Individuals were separated into two groups, either reporting taking DIM (N = 909) or reporting not taking DIM (N = 18,385). Comparisons between individuals in these two groups were made using the Wilcoxon rank sum test. Additionally, we were also able to explore a subset of women who had laboratory results in the database before and after initiating DIM treatment (N = 53). In this subset, differences were assessed with Wilcoxon signed rank tests. Results In the larger group that was separated into women reporting either DIM use or no use, significant differences were observed in the concentrations of almost every urinary estrogen and estrogen metabolite (with the only exception being 2-methoxyestrone) in the urinary estrogen profiles of those taking DIM compared to those not taking DIM (all P values < 0.001). In the smaller subset of individuals with results before and after initiating DIM use, differences were only seen in 4 of the urinary estrogens and estrogen metabolites (P < 0.001 for estrone, estradiol, estriol, and 16-hydroxyestrone). Differences in total estrogens were significant in both the larger group and the smaller subset (both with P < 0.001). Additionally, observed differences in the ratios of metabolites followed a similar trend with more significant differences observed in the larger group. Notably, the 2-hydroxyestrone:16-hydroxyestrone ratio increased significantly in both the larger group and the smaller subset with results before and after DIM use. Conclusions The results of this study provide the most comprehensive evaluation to date of DIM’s effect on the urinary estrogen profile. Additionally, the results demonstrate that the dried urine collection and accompanying assay used capture changes that are similar in direction, but not necessarily magnitude, to previous reports in the literature. Considered together, these two things highlight the clinical validity and utility of this approach to the evaluation of DIM supplementation and suggest the need for additional studies using this approach to fully understand the potential clinical utility of DIM.

show abstract

Effect of Diindolylmethane on Estrogen-related Hormones, Metabolites and Tamoxifen Metabolism: Results of a Randomized, Placebo-controlled Trial

Cited by 3 publications

References 0 publications

Exploring the Impact of 3,3’-Diindolylmethane on the Urinary Estrogen Profile of Premenopausal Women

Exploring the Impact of 3,3’-Diindolylmethane on the Urinary Estrogen Profile of Premenopausal Women

The Interplay between Microbiota and Chemotherapy-Derived Metabolites in Breast Cancer

Exploring the impact of 3,3’-diindolylmethane on the urinary estrogen profile of premenopausal women

Contact Info

Product

Resources

About